Bile Duct Cyst

Key Findings

1. Disease Information, Identifiers, and the Todani Classification (F015)

Choledochal cysts are rare congenital cystic dilatations of the intra- and/or extrahepatic biliary tree, first described by Vater and Ezler in 1723. Key identifiers are: MONDO:0018805; MeSH D015529 (Choledochal Cyst); ICD-10 Q44.4 (congenital); ICD-11 LB20.2; Orphanet ORPHA:33313. Common synonyms/alternative names include congenital biliary dilatation, choledochal malformation, bile duct cyst, and cystic dilatation of the bile duct. In 1977, Todani and colleagues modified the original Alonso-Lej (1959) scheme into five types [PMID: 28364277]:

A Type VI variant (cystic-duct involvement) has been proposed beyond the classical scheme [PMID: 34377608]. As the source review states: "In 1977, Todani and colleagues modified the original Alonso-Lej classification to include five types of CC. Type I and IV are the most common and most likely to be associated with malignancy" [PMID: 28364277]. Information for this entry derives from aggregated disease-level clinical/surgical case series and reviews, not individual EHR data.

Ontology anchors: MONDO:0018805; UBERON:0001174 (common bile duct).

2. Etiology — Two Competing Theories; Non-Mendelian Basis (F017)

The exact cause of CC is unknown and likely multifactorial. Two dominant theories persist [PMID: 35741793; PMID: 25588714]:

1. The pancreaticobiliary maljunction (reflux) theory (Babbitt, 1969): an anomalous long common channel permits reflux of activated pancreatic juice into the bile duct, causing chronic inflammation, mural weakening, and cystic dilatation.
2. The congenital stenosis/obstruction theory: antenatal distal biliary obstruction (or unequal epithelial proliferation during embryologic duct development) produces proximal ductal dilatation.

These are not mutually exclusive, and different Todani subtypes may arise by different mechanisms. Crucially, "Although family cases or CC associated with other anomalies have been reported, the molecular pathogenesis of CC is still poorly understood" [PMID: 35741793]. No single Mendelian gene has been established; the disorder is regarded as sporadic/multifactorial, so there is no diagnostic genetic test, carrier screening, or defined inheritance pattern. The initiating lesion (PBM) is congenital, forming in embryogenesis when the terminal bile duct joins a ventral pancreatic duct outside the duodenal wall. No specific environmental toxin, lifestyle factor, or infectious agent is established as causal; the primary "environmental" driver is the endogenous mixture of refluxed pancreatic juice and bile acting on the biliary epithelium.

3. Epidemiology — Female Predominance and Asian Clustering (F001, F012)

CC shows a strong female predominance and a striking East–West geographic gradient. Incidence is ~1 in 1,000 live births in Asian populations versus much rarer in the West; a Finnish nationwide series documented a rising estimated incidence from 1:128,000 to 1:38,000 over 37 years (p=0.017) [PMID: 25123318]. Female:male ratios in surgical cohorts range from ~2.3:1 in adults to ~3.6:1 in children (62 girls/17 boys in a Korean series [PMID: 41368339]; ~71% female in the Finnish series [PMID: 25123318]).

"the estimated total incidence rose from 1:128,000 to 1:38,000 (p = 0.017). Cystic CMs (42%) presented at younger age than fusiform CMs (47%) (0.8 vs. 4.6 years, p = 0.001)" [PMID: 25123318]. Malignancy risk is "more than 10% after the second decade of life in Asian patients" [PMID: 31341359]. There is no established Mendelian inheritance, penetrance, founder effect, or consanguinity role — the female/Asian predominance is unexplained at the molecular level.

4. Clinical Phenotypes — The Age-Dependent Triad (F006, F014)

The classic triad is abdominal pain + jaundice + a palpable right-upper-quadrant mass, but the complete triad is uncommon and strongly age-dependent. In a 42-patient series, only 1 child (and no adult) had all three; children were far more likely to have ≥2 of the 3 signs (82% vs 25%, p<0.05), whereas adults most commonly presented with abdominal pain misattributed to pancreatitis (23%) [PMID: 7979612]. In a 79-patient series, "the classic triad of jaundice, abdominal pain, and a mass was 6.7 times more common in group A [children] than in group B [adults]" [PMID: 19701664].

Component frequencies (13-patient series): right-upper-quadrant pain ~85%, jaundice ± cholangitis ~54%, palpable mass ~38% [PMID: 14768318]. Giant cysts (>10 cm) show pain and lump in 100% and the full triad in 60% versus only 14% for smaller cysts [PMID: 23686589]. Antenatally detected cases present as an asymptomatic fetal abdominal/hepatic cyst [PMID: 38582706]. Symptoms are typically episodic/fluctuating (recurrent cholangitis, colicky pain); severity ranges from asymptomatic (antenatal/incidental) to severe (perforation, secondary biliary cirrhosis, portal hypertension). Quality-of-life impact is driven by recurrent cholangitis/pancreatitis, the burden of major surgery, and the anxiety of lifelong cancer surveillance.

5. Mechanistic Causal Chain — From Maljunction to Carcinoma (F002, F010, F011)

This is the mechanistic heart of the disease. The ordered causal chain from initiating lesion to clinical manifestation:

(1) Congenital pancreaticobiliary maljunction (PBM)
    — pancreatic + bile ducts join OUTSIDE duodenal wall,
      long common channel >=6 mm, sphincter of Oddi cannot regulate junction
     |  LEADS TO
     v
(2) Pancreatobiliary reflux
    — pancreatic-duct pressure > bile-duct pressure ->
      persistent reflux of activated pancreatic enzymes into biliary tree
     |  RESULTS IN
     v
(3) Chronic biliary epithelial injury
    — refluxed enzymes + bile stasis + increased intraductal bile-acid concentration
     |
      +------+-----------------------------+
      v (branch A: dilatation)             v (branch B: carcinogenesis)
(5) increased intraductal pressure    (4) injury-repair cycles ->
    + distal obstruction                  epithelial HYPERPLASIA with
    (protein plugs, fatty-acid              early random KRAS mutation
    calcium stones) ->                          |
    CYSTIC/FUSIFORM DILATATION                  v
    = the choledochal cyst            (6) DYSPLASIA -> CARCINOMA sequence
                          EARLY: KRAS, microsatellite instability,
                                 COX-2, bcl-2, telomerase, HDAC1, AID, IL-33
                          LATE:  cyclin D1, beta-catenin, DPC-4/Smad4,
                                 stepwise TP53 accumulation
                                   |  CULMINATES IN
                                   v
                       (7) Cholangiocarcinoma / gallbladder carcinoma
                           (20-30x risk; mean age ~32 y)

Supporting evidence. The pressure-driven reflux step: "Since hydrostatic pressure within the pancreatic duct is usually higher than that in the common bile duct, pancreatic juice frequently refluxes into the bile duct. As a result, pancreatic enzyme levels are generally very high in the bile and there is a related high incidence of biliary cancer" [PMID: 19896105]. The histologic sequence: "Pathological findings strongly suggest a hyperplasia-dysplasia-carcinoma sequence... Reflux of pancreatic enzymes, amylase, bile stasis, and an increased intraductal concentration of bile acids contribute to proliferative activity" [PMID: 17187167].

Temporal ordering of molecular events: "While microsatellite instability, k-ras mutations, expression of COX-2 and bcl-2, and increased telomerase activity seem to occur early; involvement of cyclin D1, beta-catenin, DPC-4/Smad4 and p53 appear later in carcinogenesis" [PMID: 17187167].

The primacy of TP53 over KRAS. A laser-capture-microdissection NGS study (n=64) documented a stepwise TP53 accumulation across the injury-to-cancer field: control epithelium 10% → PBM epithelium without cancer 10% → peritumoral mucosa 38% → tumor tissue 75% (p<0.01); "TP53 alteration more than KRAS mutation was revealed to underlie carci[nogenesis]" [PMID: 34798839]. In frank cancer, KRAS is not PBM-specific: PBM-associated gallbladder cancer 16% (5/32) vs non-associated 8% (4/49), p=0.272 [PMID: 30882917]. Conversely, the inflammatory cytokine IL-33 mRNA is significantly overexpressed in PBM-associated gallbladder cancer and its background mucosa (p<0.001) [PMID: 30882917]. Even in childhood, "The Ki-67 labeling index... and expressions of KRAS, p53, HDAC, and AID in the gallbladder epithelium were significantly higher... BTC may develop later in children with CBD and in adults with PBM, via HDAC and AID expression and through epigenetic and genetic regulation" [PMID: 34132887].

Molecular pathways implicated in biliary carcinogenesis: TGF-β/Smad, IL-6/STAT-3, PI3K/AKT, Wnt, RAF/MEK/MAPK, and Notch [PMID: 24895231].

Ontology anchors: GO:0006954 (inflammatory response); GO:0008283 (cell population proliferation); CL:0000069 (biliary epithelial cell/cholangiocyte); CHEBI:3098 (bile acid).

6. Genetic / Molecular Information (F011, F017)

CC has no established causal Mendelian gene; it is sporadic/multifactorial [PMID: 35741793]. The molecular findings are those of somatic carcinogenesis in the injured epithelium, not germline disease-causing variants:

The genes involved are germline-wild-type / somatically altered; the functional consequence is loss of tumor-suppressor function (TP53, RB1, DPC-4/Smad4) and gain-of-function oncogenic signaling (KRAS, ERBB2/EGFR). Epigenetic dysregulation (HDAC1, AID) plus microsatellite instability (~60% of dysplasia) contribute even in childhood [PMID: 34132887; PMID: 14534681]. For Type V (Caroli disease), when part of the ARPKD spectrum, the relevant gene is PKHD1 (fibrocystin) — see animal models below. No recurrent chromosomal abnormality (aneuploidy, translocation) is characteristic of CC.

Ontology anchors: HGNC:11998 (TP53), HGNC:6407 (KRAS), HGNC:9024 (PKHD1).

7. Anatomical Structures and Histopathology (F009)

The primary site is the extrahepatic/common bile duct (UBERON:0001174), with secondary involvement of the gallbladder (UBERON:0002110), intrahepatic bile ducts (UBERON:0001172), liver (UBERON:0002107), and pancreatic duct/common channel (UBERON:0009976). The affected body system is the digestive/hepatobiliary system. The target cell is the biliary epithelial cell/cholangiocyte (CL:0000069); the tissue is glandular/columnar epithelium with associated smooth muscle and connective tissue of the duct wall.

Cyst-wall histology shows "ulceration, inflammation, fibrosis, and metaplasia" [PMID: 24604978] — specifically loss of the columnar epithelial lining, absent/attenuated smooth muscle, dense fibrosis, chronic inflammation, and glandular/intestinal metaplasia. Intracholedochal cystic pressure (mean ~15 mmHg) correlates directly with hepatocellular damage and cholestasis and inversely with cyst-wall inflammatory change and bile amylase [PMID: 24604978]. Lateralization is not applicable (midline biliary structure); intrahepatic involvement (Types IVa/V) may be uni- or bilobar.

8. Temporal Development (F001, F004, F012, F019)

• Onset: Congenital (initiating lesion in embryogenesis); clinical onset ranges from antenatal detection through neonatal, pediatric, and adult presentation. Onset pattern is chronic/insidious, punctuated by acute episodes (cholangitis, pancreatitis). Cystic malformations present younger (median 0.8 y) than fusiform types (median 4.6 y) [PMID: 25123318].
• Progression: Chronic, lifelong. Cancer risk is age-dependent — "The cancer-risk is low in childhood (<1% in the first decade), and shows a clear increase with age" [PMID: 17187167], rising to 10–30% in adults.
• Critical window: Complete excision removes the reflux-injured epithelium; earlier surgery (even before 6 months) improves prognosis regarding intrahepatic-duct stones [PMID: 40097690]. Residual cancer risk rises sharply beyond 15 years post-excision [PMID: 22989043]. Disease course is not self-limiting; without excision it is a chronic, progressive, premalignant condition.

9. Diagnostics — MRCP as the Gold Standard (F008, F016)

Diagnosis uses multimodality imaging — ultrasound (first-line, often diagnostic for smaller cysts), CT, MRI/MRCP, ERCP, and PTC. MRCP has replaced the more invasive ERCP/PTC as the gold standard: "MRCP has replaced the more invasive techniques as the gold standard of diagnosis. In addition, MRCP is helpful in detecting an abnormal pancreaticobiliary junction, which is seen in the majority of choledochal cysts" [PMID: 25682292]. In a giant-cyst series, US/CT were misleading but "Magnetic resonance cholangiopancreatography correctly achieved the diagnosis in all" [PMID: 23686589].

Diagnostic criteria for PBM (Japanese guidelines): an abnormally long common channel (≥6 mm) and/or an abnormal pancreaticobiliary junction outside the duodenal wall on direct cholangiography, MRCP, EUS, or MDCT; an elevated biliary amylase supports pancreatobiliary reflux [PMID: 25404143; PMID: 22722902]. Supportive labs show an obstructive/cholestatic pattern (↑ bilirubin, ALP, GGT; LOINC-codable liver panel). There is no genetic or newborn-screening test because the disorder is non-Mendelian; CA19-9 serves as a follow-up tumor marker rather than a diagnostic test.

Key differential diagnoses: Cystic biliary atresia (CBA) — "a rare variant of biliary atresia that closely resembles choledochal cyst... complicating diagnosis and potentially delaying critical surgical intervention" [PMID: 42110123] — plus hepatic cyst, mesenchymal hamartoma, hepatic hemangioma, duplication cyst, and ovarian cyst on prenatal imaging [PMID: 41553982; PMID: 41569008].

10. Treatment — Complete Excision + Roux-en-Y Hepaticojejunostomy (F003, F008, F013)

The definitive treatment is complete excision of the extrahepatic bile duct/cyst plus cholecystectomy and biliary-enteric reconstruction, preferentially Roux-en-Y hepaticojejunostomy (NCIT: Hepaticojejunostomy; NCIT: Cholecystectomy). Hepaticoduodenostomy carries higher biliary-reflux morbidity. "Roux-en-Y hepaticojejunostomy should remain the preferred reconstructive option in most children undergoing excision of choledochal malformations" [PMID: 41927966].

Risk-stratified prophylactic surgery per Japanese guidelines: PBM with dilatation → prophylactic flow-diversion (extrahepatic bile duct + gallbladder excision); PBM without dilatation → prophylactic cholecystectomy without duct resection: "in the former group, a prophylactic excision of the common bile duct and gallbladder should be recommended, while in the later group, a prophylactic cholecystectomy without bile duct resection may be the appropriate surgical procedure" [PMID: 18274840].

Minimally invasive approaches now predominate. A meta-analysis of 19 pediatric studies found robotic surgery (RS) superior to laparoscopic surgery (LS):

"the RS group had significantly lower incidences of postoperative biliary stones (OR = 0.10...), bile leakage (OR = 0.28...), anastomotic stricture (OR = 0.27...), and overall complications (OR = 0.26...) compared to the LS group" [PMID: 42130797]. A 201-patient study confirmed lower blood loss, faster oral intake, and shorter hospital stay with RS (all p<0.05) [PMID: 40889549]; a propensity-matched cohort (n=604) confirmed lower anastomotic stricture with RS (1.32%) [PMID: 41104222]. Chemoprevention (COX-2 inhibitors, vitamin K2) is experimental only — validated in animal models but not clinical. There is no role for pharmacotherapy, gene therapy, cell therapy, or immunotherapy in the primary disease (aside from oncologic treatment once cancer develops).

11. Outcome / Prognosis — Excellent After Excision but Lifelong Residual Cancer Risk (F004, F007, F019)

With complete excision, overall prognosis is generally excellent with low perioperative mortality (5-year overall survival ~95.5% in a 394-patient series [PMID: 25923827]). However, a residual lifelong cancer risk persists in retained duct segments — estimated up to ~4% after operation, with pre-operative adult malignancy risk of 6–30% [PMID: 29258149]. A 94-patient cohort quantified the time-dependence:

"The risk of biliary malignancy in the remnant bile duct increases more than 15 years after cyst excision" [PMID: 22989043]. Once malignancy develops, prognosis is dismal: "The overall cumulative survival rates... were 50% at 2 years and 25% at 3 years, with a median survival time of 15 months" [PMID: 22989043]. Cancer can appear even ~36 years after resection [PMID: 39845966], and regular follow-up has not clearly improved resectability [PMID: 27307284].

Type I and IV cysts show higher cancer incidence even after excision [PMID: 17187167]. Caroli disease/syndrome (Type V) carries the worst prognosis: in a longitudinal cohort, "All cases of esophageal varices, hepatic decompensation, cholangiocarcinoma (n=3), and death (n=3) occurred exclusively in the CS [Caroli syndrome] group" [PMID: 41888235]; cholangiocarcinoma in ~5–19%, and 5-year survival after liver resection ~88.5% but only ~33% at 1 year if cholangiocarcinoma is present [PMID: 24121258; PMID: 29929811]. Prognostic factors include patient age, Todani cyst type, histology, and localization [PMID: 29258149].

Late complications after excision: anastomotic stricture/stenosis (diameter <3 mm), intrahepatic duct stones (esp. Todani IVa), remnant intrapancreatic stones, cholangitis, and secondary biliary cirrhosis. Late complications occur in ~36% (8/22) of long-followed pediatric patients at median 12 years [PMID: 41638356].

12. Prevention (F008, F020)

Prevention is dominated by surgical and surveillance strategies:

• Primary/secondary (cancer prevention): Prophylactic complete excision + cholecystectomy + Roux-en-Y hepaticojejunostomy at diagnosis, removing the reflux-injured premalignant epithelium; for PBM without dilatation, prophylactic cholecystectomy [PMID: 23798483; PMID: 19896105].
• Surgical refinement: A Carrel-patch hepaticojejunostomy widening the anastomosis to 10–13 mm reduced stenosis and intrahepatic stones and "appears to be oncologically safe because of the absence of malignant transformation for at least 20 years" [PMID: 36574035]. Obsolete internal-drainage procedures (cystenterostomy) leave the cyst in situ and carry high later cancer risk.
• Tertiary (surveillance): Lifelong follow-up. "A postoperative follow-up concept that consists of annual controls of CA19-9 and abdominal ultrasound is introduced" [PMID: 29258149].
• Chemoprevention (experimental): In animal PBM models, COX-2 inhibitors (meloxicam) and vitamin K2 suppress carcinogenesis — not yet clinical [PMID: 15944215; PMID: 21661384].
• Not applicable: No vaccine, no genetic/carrier screening, no population newborn screening (sporadic/non-Mendelian); genetic counseling is generally not indicated beyond noting rare familial clustering.

13. Other Species / Natural Disease and Model Organisms (F005, F009, F018)

Natural disease in other species. Naturally occurring choledochal cysts are documented in domestic shorthair cats (NCBI Taxon 9685): "Histologically, the cyst wall was expanded by fibroblasts, collagen, and lymphoplasmacytic inflammation", with secondary neutrophilic cholangitis, choledochitis, duodenal papillitis, and pancreatitis [PMID: 34027760]. This documents cross-species (comparative) pathology; there is no established zoonotic transmission.

Model organisms.

The DBTC rat model showed "the bile duct had been gradually dilated on day 3... the biliary epithelium... was papillary proliferated on day 7... HDAC1 expression increased at the early postoperative period prior to other oncogene" [PMID: 26176076], implicating HDAC1 as an upstream driver acting via COX-2. Chemoprevention is demonstrable: the COX-2 inhibitor meloxicam reduced atypical epithelium from 72.7% to 27.3% with no cancer (PCNA index p=0.045) [PMID: 15944215], and vitamin K2 (menaquinone-4) "suppressed biliary carcinogenesis by the induction of cell cycle arrest" [PMID: 21661384]. The PCK rat is the definitive Caroli model — an "autosomal recessive" PKHD1/fibrocystin-deficient mutant [PMID: 11337358] showing plasmin/tPA-mediated basement-membrane (laminin, type IV collagen) degradation [PMID: 19025978]. Model limitations: surgical APBDU models capture reflux-driven dilatation but not the full decades-long human carcinogenesis timeline; the PCK rat models only Type V (Caroli), not the reflux-driven Types I–IV.

Mechanistic Model / Interpretation

The unifying insight from this investigation is that a single congenital anatomic lesion (pancreaticobiliary maljunction) drives two clinically distinct outcomes through one shared intermediate (chronic reflux-mediated epithelial injury):

      CONGENITAL PBM (long common channel >=6 mm)
            |
      pancreatic-duct pressure > bile-duct pressure
            |
  PANCREATOBILIARY REFLUX
     (activated enzymes + bile stasis + high bile acids)
            |
      CHRONIC BILIARY EPITHELIAL INJURY-REPAIR
     /                      \
      MECHANICAL branch              MOLECULAR branch
   increased intraductal pressure   hyperplasia (early KRAS/COX-2/
   + protein plugs/stones            HDAC1/AID/IL-33)
  |                              |
   CYSTIC DILATATION            dysplasia -> carcinoma
   (the choledochal cyst)       (late stepwise TP53 10% -> 75%)
  |                              |
   presents as triad,           CHOLANGIOCARCINOMA /
   cholangitis, pancreatitis    GALLBLADDER CARCINOMA
                (20-30x; mean age ~32 y)

This model explains several otherwise puzzling clinical facts. First, why surgical flow-diversion (excision + Roux-en-Y) is curative for the cyst yet incompletely protective against cancer: excision removes the bulk of injured epithelium and stops reflux, but any retained duct remnant that has already accumulated somatic mutations (a "field defect") can still progress — hence the late-rising residual risk beyond 15 years. Second, why cancer risk is age-dependent: the molecular hits accumulate stepwise over decades (TP53 rising 10%→75% across the field), so childhood risk is <1% but adult risk reaches 10–30%. Third, why PBM without dilatation still warrants prophylactic cholecystectomy: the carcinogenic reflux acts on the gallbladder regardless of whether the duct dilates (gallbladder cancer reaches 36–88% in PBM without dilatation). The mechanistic chain from PBM through reflux to the hyperplasia–dysplasia–carcinoma sequence is well demonstrated in human tissue and validated in surgical and chemical animal models; the specific ordering (KRAS early, TP53 late, HDAC1 upstream) is supported but based on cross-sectional tissue-field comparisons rather than longitudinal lineage tracing.

Evidence Base

Convergent vs challenging evidence. The reflux/PBM etiology is strongly convergent across human tissue studies, guidelines, and multiple animal models. The main challenge to a simple monocausal model comes from the persistence of the "congenital obstruction" theory [PMID: 25588714] and the observation that not all CC (e.g., some Type V/Caroli, which is a ductal-plate/ARPKD disorder) involve PBM at all — indicating etiologic heterogeneity across Todani subtypes. A single intracholecystic-papillary-neoplasm case report found neither KRAS nor p53 alteration despite PBM [PMID: 33168026], reminding us that not every PBM-associated tumor follows the canonical pathway.

Limitations and Knowledge Gaps

1. Non-Mendelian, poorly characterized genetics. No germline causal gene is established for classic (Types I–IV) CC. The genomics/transcriptomics literature is nascent, and candidate susceptibility loci or modifier genes remain undefined [PMID: 35741793]. The molecular explanation for the female and Asian predominance is unknown.
2. Cross-sectional molecular ordering. The KRAS-early/TP53-late sequence and the HDAC1-upstream hypothesis rest on cross-sectional tissue-field comparisons and animal models, not longitudinal human lineage tracing.
3. Etiologic heterogeneity. The two-theory debate (reflux vs congenital obstruction) is unresolved; different Todani subtypes likely have distinct mechanisms, and Type V (Caroli) is mechanistically separate (ductal-plate malformation/PKHD1).
4. Surveillance efficacy uncertain. Regular post-excision follow-up has not been clearly shown to improve resectability or survival of remnant-duct cancer [PMID: 27307284]; optimal surveillance intervals and modalities are unvalidated.
5. No clinical chemoprevention. COX-2 inhibitors and vitamin K2 are validated only in animals; human chemoprevention trials are absent.
6. Western data are sparse relative to Asian series; incidence and outcome estimates may not transfer across populations.

Proposed Follow-up Experiments / Actions

1. Longitudinal molecular field mapping. Use spatial transcriptomics/multi-region sequencing on excised cyst walls to directly test the proposed KRAS-early → TP53-late → HDAC1-upstream causal ordering and identify a molecular signature predicting remnant-duct cancer risk.
2. Germline discovery. Conduct whole-genome/exome sequencing on familial and syndromic CC cohorts (and trio designs) to search for susceptibility variants explaining the female and Asian predominance.
3. Prospective surveillance trial. Design a registry-based study testing whether a defined CA19-9 + MRCP surveillance schedule improves early detection and survival of post-excision remnant cancers.
4. Chemoprevention translation. Given robust animal data, evaluate COX-2 inhibitors or vitamin K2 in high-risk patients who cannot undergo complete duct clearance (e.g., intrahepatic remnants).
5. Robotic vs laparoscopic long-term RCT. Extend current short-term comparative data with a prospective trial powered for long-term anastomotic stricture, intrahepatic stones, and cancer.
6. Biomarker development for cystic biliary atresia differentiation. Develop a prenatal/neonatal imaging + biomarker algorithm to reliably distinguish CBA (needs urgent Kasai) from CC.

Report compiled from a 10-iteration autonomous investigation: 20 confirmed findings, 5 supported hypotheses, 87 papers reviewed.

Artifacts

• OpenScientist final report
• OpenScientist final report

Citations

1. PMID:28364277
2. PMID:34377608
3. PMID:35741793
4. PMID:25588714
5. PMID:25123318
6. PMID:41368339
7. PMID:40570483
8. PMID:19701664
9. PMID:31341359
10. PMID:7979612
11. PMID:14768318
12. PMID:23686589
13. PMID:38582706
14. PMID:19896105
15. PMID:17187167
16. PMID:34798839
17. PMID:30882917
18. PMID:34132887
19. PMID:24895231
20. PMID:14534681
21. PMID:24604978
22. PMID:40097690
23. PMID:22989043
24. PMID:25682292
25. PMID:25404143
26. PMID:22722902
27. PMID:42110123
28. PMID:41553982
29. PMID:41569008
30. PMID:41927966
31. PMID:18274840
32. PMID:42130797
33. PMID:40889549
34. PMID:41104222
35. PMID:25923827
36. PMID:29258149
37. PMID:39845966
38. PMID:27307284
39. PMID:41888235
40. PMID:24121258
41. PMID:29929811
42. PMID:41638356
43. PMID:23798483
44. PMID:36574035
45. PMID:15944215
46. PMID:21661384
47. PMID:34027760
48. PMID:17021737
49. PMID:9434012
50. PMID:8986984
51. PMID:26176076
52. PMID:11337358
53. PMID:20017109
54. PMID:19025978
55. PMID:18500533
56. PMID:33168026